Selank vs Semax: Comparing Nootropic Peptides for Research (UK 2026)

Selank and Semax are two Russian-developed neuropeptides with overlapping research applications in cognitive enhancement, anxiolysis, neuroprotection, and stress modulation. They are often studied and discussed together because both act on the central nervous system through related mechanisms involving neurotrophic factors — yet their pharmacological profiles are distinct enough that they serve different research purposes.

This guide provides a direct comparison of both compounds for researchers evaluating which tool best fits their experimental question.

Origins and Structure

Selank is a heptapeptide (7 amino acids) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is a synthetic analogue of the endogenous immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg), extended with the sequence Gly-Glu-Glu to improve stability. Its development focused on finding anxiolytic compounds without the dependence and cognitive impairment liabilities of benzodiazepines.

Semax is a heptapeptide fragment of the ACTH(4-10) sequence — the melanocyte-stimulating portion of adrenocorticotrophic hormone — with a Pro-Gly-Pro extension for improved stability and CNS penetrance. It was developed at the Institute of Molecular Genetics in collaboration with Moscow State University and has been used clinically in Russia as a nasal spray (Semax® and Semax 1%) for stroke, cognitive decline, and optic nerve disease.

Primary Mechanisms

Selank’s primary mechanisms include: BDNF (brain-derived neurotrophic factor) upregulation — increasing expression of this critical neuroplasticity factor in the hippocampus and prefrontal cortex; modulation of the GABAergic system, producing anxiolytic effects through a pathway distinct from benzodiazepines; serotonin metabolism enhancement through tryptophan hydroxylase and MAO-A modulation; IL-6 and enkephalin system interactions; and tuftsin-like immunomodulatory activity.

Semax’s primary mechanisms include: BDNF upregulation (shared with Selank, but typically considered stronger); VEGF (vascular endothelial growth factor) upregulation — promoting cerebral angiogenesis and neuronal survival; NGF (nerve growth factor) and NT-3 upregulation; serotonin and dopamine metabolism modulation in limbic and prefrontal regions; and neuroprotection against ischaemia via antioxidant enzyme upregulation and anti-apoptotic signalling.

Cognitive Enhancement Research

Selank in cognitive research: studies in rodents demonstrate improvements in associative learning, spatial memory in maze tasks, and attention under distraction conditions. The proposed mechanism is BDNF-mediated enhancement of synaptic plasticity in hippocampal circuits, with secondary contributions from reduced anxiety (which impairs cognitive performance).

Semax in cognitive research: Russian clinical research (using Semax nasal spray) has examined Semax in stroke recovery, children with developmental delay, and optic nerve atrophy. Results show improvements in attention, cognitive processing speed, and memory consolidation. The BDNF + VEGF dual mechanism gives Semax broader potential for neuroprotective and recovery-oriented cognitive research, particularly where ischaemia or oxidative damage is involved.

For pure nootropic cognitive enhancement research (healthy subjects, learning and memory endpoints): both compounds are relevant, with Semax typically considered the stronger cognitive-enhancing tool based on its more potent BDNF upregulation and the clinical research base. For anxiety-related cognitive impairment: Selank may be more targeted, as its anxiolytic properties directly address the anxiety-cognition interaction.

Anxiety and Stress Research

Selank is the clearer choice for anxiolytic research. Its development was explicitly targeted at producing anxiolysis without benzodiazepine side effects. In rodent anxiety models (elevated plus maze, open field, Vogel conflict), Selank consistently reduces anxiety-like behaviour at doses that do not cause sedation, motor impairment, or memory disruption. Its GABAergic mechanism produces anxiolysis through a positive allosteric modulation route distinct from direct benzodiazepine binding.

Critically, Selank does not produce tolerance or dependence in animal models — making it scientifically interesting for researchers studying alternatives to current anxiolytic pharmacology.

Semax has stress-modulating properties through its influence on dopamine and serotonin systems, but its primary profile is neuroprotective and nootropic rather than anxiolytic. For studies where the primary endpoint is anxiety reduction, Selank is the more appropriate tool.

Neuroprotection Research

Semax leads decisively in neuroprotection research. Its VEGF upregulation promotes cerebral angiogenesis and neuronal survival under ischaemic conditions — a mechanism directly relevant to stroke, TBI, and neurodegeneration research. Russian studies in ischaemic stroke patients using Semax nasal spray documented improved functional outcomes and biomarker changes consistent with enhanced neuronal survival. Its antioxidant enzyme upregulation (SOD, catalase) protects against reactive oxygen species that mediate ischaemia-reperfusion injury.

Selank has neuroprotective properties mediated through BDNF upregulation and anti-inflammatory effects, but lacks Semax’s VEGF angiogenic mechanism. For researchers designing neuroprotection, stroke recovery, or TBI studies, Semax is typically the more appropriate compound.

Immunomodulation

Selank has documented immunomodulatory effects derived from its tuftsin-based structure. Tuftsin is a natural tetrapeptide involved in neutrophil and macrophage activation. Selank modulates IL-6 production, influences the Th1/Th2 balance, and has been studied in immune stress models. For researchers interested in the neuroimmune interface — the bidirectional communication between the nervous and immune systems — Selank’s dual anxiolytic-immunomodulatory profile is particularly interesting.

Semax has indirect immune effects through stress system modulation but is not primarily studied as an immunomodulator.

Administration and Stability

Both peptides are most commonly administered as nasal sprays in Russian clinical use, taking advantage of the nasal mucosa’s direct connection to the CNS via the olfactory nerve — bypassing the blood-brain barrier. For research purposes, intranasal, intravenous, and subcutaneous routes are all studied.

Selank is stable in solution at pH 5–7 and maintains potency for several weeks at 4°C after reconstitution. Semax has similar stability characteristics. Both are more stable than many other research peptides, making them practical to work with in laboratory settings.

Summary: Which to Use When

For anxiety and stress research: Selank is the more targeted choice with the stronger anxiolytic evidence base. For neuroprotection and stroke research: Semax is clearly preferred, given its VEGF mechanism and clinical Russian research base. For cognitive enhancement research in healthy subjects: both are relevant; Semax is considered more potent for BDNF-mediated plasticity effects. For neuroimmune research: Selank’s tuftsin-based immunomodulatory profile is unique. For combined anxiety-cognition research: Selank offers the advantage of addressing both endpoints simultaneously through complementary mechanisms.

Many researchers include both compounds in the same study as comparison arms, given that their mechanisms are complementary and the question “which nootropic peptide produces better [outcome]” is itself scientifically interesting.